Abstract: A method is disclosed that includes providing an IP bank, an application bank, and a technology bank; generating a hierarchical table based on the IP bank and the application bank; performing an estimation of at least one of a performance value, a power value, an area value and a cost value, which corresponds to the hierarchical table, by using the technology bank, to output an result data as a basis of fabrication of a system.

Abstract: A method of fabricating a poly-crystalline silicon ingot includes: (a) loading a nucleation promotion layer onto a bottom of a mold; (b) providing a silicon source on the nucleation promotion layer in the mold; (c) heating the mold until the silicon source is melted into a silicon melt completely; (d) controlling at least one thermal control parameter regarding the silicon melt continually to enable the silicon melt to nucleate on the nucleation promotion layer such that a plurality of silicon grains grow in the vertical direction; (e) controlling the at least one thermal control parameter to enable the plurality of the silicon grains to continuously grow with an average grain size increasing progressively in the vertical direction until entirety of the silicon melt is solidified to obtain the poly-crystalline silicon ingot, wherein the nucleation promotion layer is loaded by spreading a plurality of mono-Si particles over the bottom of the mold.

Abstract: Provided is a method of detecting a defect of a pattern using vectorization to increase accuracy and efficiency in OPC modeling and OPC verification. The method includes acquiring a target layout image associated with a target pattern, acquiring a pattern image associated with a pattern formed on a substrate, extracting an edge image from the pattern image, producing a first vector form based on the target layout image, producing a second vector form based on the edge image, and comparing the first vector form with the second vector form.

Abstract: Embodiments of the present invention relate to a liquid crystal grating and a control method thereof, and a 3D touch display panel. The liquid crystal grating, comprises: upper and lower substrates; a liquid crystal layer, arranged between the two substrates; a plurality of strip-shaped electrode groups, parallel to each other and arranged side by side, and formed on a surface of the upper substrate facing the liquid crystal layer, each of the electrode groups including first and second comb-shaped touch electrodes separated by a strip-shaped region, comb teeth of the first and second touch electrodes being opposite to each other, and an included angle between extending directions of the strip-shaped region and the electrode group being an acute angle; first and second comb-shaped grating electrodes, formed on a surface of the lower substrate facing the liquid crystal layer, the first and second grating electrodes being arranged in an interdigital shape.

Abstract: A display in a portable information handling system may have a narrow or no border. A display panel cover included with the display may be formed with an insert molding that is co-molded with an outer panel for high bonding strength and high stiffness, as well as providing a desired high quality external appearance to information handling system. Additionally, an exterior insert molding may be formed to include an exterior surface of the information handling system.

Abstract: A display in a portable information handling system may have a narrow or no border. A display panel cover included with the display may be formed with an insert molding that is co-molded with an outer panel for high bonding strength and high stiffness, as well as providing a desired high quality external appearance to information handling system.

Abstract: Methods of inhibiting platelet aggregation using antibodies having binding specificity for the ? subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing thrombosis in a subject using such antibodies.

Abstract: Methods of inhibiting platelet aggregation using antibodies having binding specificity for the ? subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing or treating thrombosis in a subject using such antibodies.

Abstract: A crystalline silicon ingot and a method of fabricating the same are provided. The method utilizes a nucleation promotion layer to facilitate a plurality of silicon grains to nucleate on the nucleation promotion layer from a silicon melt and grow in a vertical direction into silicon grains until the silicon melt is completely solidified. The increment rate of defect density in the silicon ingot along the vertical direction has a range of 0.01%/mm˜10%/mm.

Abstract: The present invention provides modified natural killer T (NKT) cells, pharmaceutical compositions comprising the modified NKT cells and at least one pharmaceutically acceptable carrier or excipient, and uses of the modified NKT cells. Also disclosed herein are methods for enriching NKT cells and generating the modified natural killer T cells.

Abstract: A software test apparatus and a software test method and a computer readable medium thereof are provided. The software test apparatus stores a software testing program, an under-tested code, a plurality of basic test benches and a plurality of candidate test benches. The under-tested code includes a hard-to-detect code and the hard-to-detect code has at least one hard-to-detect section. The software test apparatus runs the software testing program to execute the following operations: parsing the hard-to-detect code to generate a condition-statement tree; based on the basic test benches and the condition-statement tree, using a support vector machine (SVM) to establish a support vector regression (SVR) predictor; and applying the SVR predictor to choose a best candidate test bench from the candidate test benches.

Abstract: Disclosed is a device and method for detecting types of a universal serial bus cable. The detection device includes a detection circuit and a control unit. The detection circuit includes a signal source, a receiving end, a first resistor, a second resistor, a variable resistor, a first capacitor, a second capacitor, first through fourth switches, a VBUS end, an ID end, and a ground end. The signal source provides a detection signal. The control unit is electrically connected to the detection circuit, and is configured to control the first through the fourth switches according to a plurality of on-off states, to receive the detection signal and a VBUS signal from the receiving end in the plurality of on-off states, to generate a plurality of detection results, and to determine the type of the USB cable according to the plurality of detection results.

Abstract: Activation sites on the alpha subunit of sodium potassium ATPase have been discovered. It has also been discovered that certain antibodies that bind to the alpha subunit of sodium potassium ATPase dramatically increase enzyme activity. There has never before been a report of precise activation sites or drug interaction sites for sodium potassium ATPase. Certain methods have also been discovered for treating or preventing diseases associated with low sodium potassium ATPase activity by administering antibodies, antibody fragments and small molecules that bind to the activation sites on the alpha subunit of sodium potassium ATPase.

Abstract: Activation sites on the alpha subunit of sodium potassium ATPase have been discovered. It has also been discovered that certain antibodies that bind to the alpha subunit of sodium potassium ATPase dramatically increase enzyme activity. There has never before been a report of precise activation sites or drug interaction sites for sodium potassium ATPase. Certain methods have also been discovered for treating or preventing diseases associated with low sodium potassium ATPase activity by administering antibodies, antibody fragments and small molecules that bind to the activation sites on the alpha subunit of sodium potassium ATPase.

Abstract: Antibodies binding to sites on the alpha-subunit of the (Na++K+)-ATPase increase cardiac contraction of both ventricular myocytes and mouse heart. In particular, antibodies binding to the RSATEEEPPNDD (SEQ ID NO: 1) or DVEDSYGQQTYEQR (SEQ ID NO: 2) peptides (or isoforms/derivatives thereof) of the alpha-subunit of the (Na++K+)-ATPase, have been found to be highly inotropic. Both the antibodies and the peptides are important for the treatment of human heart failure and other contractile disorders.

Abstract: A display panel with an electrostatic discharge (ESD) protection function, includes a organic light emitting diode (OLED) light area, a scan driving circuit, and a data driving circuit. Therein, the OLED light area includes a number of pixel regions which are arranged in array mode. The scan driving circuit and the OLED light area are connected to each other via a number of scan lines which are fanned out. The data driving circuit and the OLED light area are connected to each other via a number of data lines which are fanned out. Therein, each data line is connected to one voltage point via a first OLED, each scan line is connected to one voltage point via a second OLED.

Abstract: Antibodies that are agonists of sodium pump (Na+/K+ ATPase; NKA) activity are provided. In particular, antibodies that specifically bind epitopes on the beta-1 (?1) subunit of NKA are disclosed. These antibodies have the ability to increase the activity of the catalytic alpha subunit of NKA upon ?1 subunit binding. Due to their activity, the antibodies also have the ability to trigger a positive inotropic effect in cardiac tissues (i.e., increase cardiac contraction). The present invention thus includes, but is not limited to, NKA ?1 subunit peptide epitopes, antibodies that specifically bind the epitopes, methods of agonizing NKA activity through administration of the peptides or the antibodies, and methods of treating and/or preventing heart disease through administration of the peptides or the antibodies.

Abstract: Antibodies binding to sites on the alpha-subunit of the (Na++K+)-ATPase increase cardiac contraction of both ventricular myocytes and mouse heart. In particular, antibodies binding to the RSATEEEPPNDD (SEQ ID NO: 1) or DVEDSYGQQWTYEQR (SEQ ID NO: 2) peptides (or isoforms/derivatives thereof) of the alpha-subunit of the (Na++K+)-ATPase, have been found to be highly inotropic. Both the antibodies and the peptides are important for the treatment of human heart failure and other contractile disorders.

Abstract: Present example embodiments relate generally to a surgical system comprising an internal anchor assembly configurable to be inserted into and positioned inside a cavity of a body. The surgical system further comprises an external anchor assembly configurable to magnetically couple to the internal anchor assembly. The external anchor assembly may comprise a magnetic assembly. The magnetic assembly may include one or more superconducting magnets configurable to generate a magnetic field. The magnetic assembly may further include a conductive housing for receiving the one or more superconducting magnets. The external anchor assembly may further include a temperature control section configurable to control a temperature of the one or more superconducting magnets via the conductive housing. The external anchor assembly may further include an external anchor body configurable to receive the magnetic assembly and the temperature control section.

Abstract: Antibodies that are agonists of sodium pump (Na+/K+ ATPase; NKA) activity are provided. In particular, antibodies that specifically bind epitopes on the beta-1 (?1) subunit of NKA are disclosed. These antibodies have the ability to increase the activity of the catalytic alpha subunit of NKA upon ?1 subunit binding. Due to their activity, the antibodies also have the ability to trigger a positive inotropic effect in cardiac tissues (i.e., increase cardiac contraction). The present invention thus includes, but is not limited to, NKA ?1 subunit peptide epitopes, antibodies that specifically bind the epitopes, methods of agonizing NKA activity through administration of the peptides or the antibodies, and methods of treating and/or preventing heart disease through administration of the peptides or the antibodies.